Shannon Westin
Shannon Westin
Ismeretlen szervezet
E-mail megerősítve itt: mdanderson.org
Cím
Hivatkozott rá
Hivatkozott rá
Év
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
F Janku, JJ Wheler, SN Westin, SL Moulder, A Naing, AM Tsimberidou, ...
Journal of clinical oncology 30 (8), 777, 2012
4522012
Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer
H Liang, LWT Cheung, J Li, Z Ju, S Yu, K Stemke-Hale, T Dogruluk, Y Lu, ...
Genome research 22 (11), 2120-2129, 2012
2542012
Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome
SN Westin, RA Lacour, DL Urbauer, R Luthra, DC Bodurka, KH Lu, ...
Journal of Clinical Oncology 26 (36), 5965, 2008
1972008
AKT inhibition in solid tumors with AKT1 mutations
DM Hyman, LM Smyth, MTA Donoghue, SN Westin, PL Bedard, EJ Dean, ...
Journal of Clinical Oncology 35 (20), 2251, 2017
1942017
A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer
PT Soliman, SN Westin, S Dioun, CC Sun, E Euscher, MF Munsell, ...
Gynecologic oncology 146 (2), 234-239, 2017
1312017
Clinical cancer advances 2018: annual report on progress against cancer from the American Society of Clinical Oncology
J Heymach, L Krilov, A Alberg, N Baxter, SM Chang, RB Corcoran, ...
Journal of Clinical Oncology 36 (10), 1020-1044, 2018
1232018
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade …
UA Matulonis, GM Wulf, WT Barry, M Birrer, SN Westin, S Farooq, ...
Annals of Oncology 28 (3), 512-518, 2017
1212017
Radical hysterectomy: a comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology
PT Soliman, M Frumovitz, CC Sun, R Dos Reis, KM Schmeler, AM Nick, ...
Gynecologic oncology 123 (2), 333-336, 2011
1192011
Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG Oncology–RTOG 1203
AH Klopp, AR Yeung, S Deshmukh, KM Gil, L Wenzel, SN Westin, ...
Journal of Clinical Oncology 36 (24), 2538, 2018
1172018
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers
C Sun, Y Fang, J Yin, J Chen, Z Ju, D Zhang, X Chen, CP Vellano, ...
Science translational medicine 9 (392), 2017
1052017
Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device
N Pal, RR Broaddus, DL Urbauer, N Balakrishnan, A Milbourne, ...
Obstetrics and gynecology 131 (1), 109, 2018
922018
Optimization of MR imaging for pretreatment evaluation of patients with endometrial and cervical cancer
GM Rauch, H Kaur, H Choi, RD Ernst, AH Klopp, P Boonsirikamchai, ...
Radiographics 34 (4), 1082-1098, 2014
902014
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
PA Konstantinopoulos, WT Barry, M Birrer, SN Westin, KA Cadoo, ...
The Lancet Oncology 20 (4), 570-580, 2019
852019
Sequential therapy with PARP and WEE1 inhibitors minimizes toxicity while maintaining efficacy
Y Fang, DJ McGrail, C Sun, M Labrie, X Chen, D Zhang, Z Ju, CP Vellano, ...
Cancer cell 35 (6), 851-867. e7, 2019
782019
Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence
A Carroll, PT Ramirez, SN Westin, PT Soliman, MF Munsell, AM Nick, ...
Gynecologic oncology 135 (3), 455-461, 2014
752014
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH …
I Brana, R Berger, T Golan, P Haluska, J Edenfield, J Fiorica, ...
British journal of cancer 111 (10), 1932-1944, 2014
732014
Overall survival after pelvic exenteration for gynecologic malignancy
SN Westin, V Rallapalli, B Fellman, DL Urbauer, N Pal, MM Frumovitz, ...
Gynecologic oncology 134 (3), 546-551, 2014
722014
A phase I open-label study to identify a dosing regimen of the pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers
U Banerji, EJ Dean, JA Pérez-Fidalgo, G Batist, PL Bedard, B You, ...
Clinical Cancer Research 24 (9), 2050-2059, 2018
712018
What women with ovarian cancer think and know about genetic testing
RA Lacour, MS Daniels, SN Westin, LA Meyer, CC Burke, KA Burns, ...
Gynecologic oncology 111 (1), 132-136, 2008
632008
Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer
ND Fleming, M Frumovitz, KM Schmeler, R Dos Reis, MF Munsell, PJ Eifel, ...
Gynecologic oncology 136 (1), 48-53, 2015
622015
A rendszer jelenleg nem tudja elvégezni a műveletet. Próbálkozzon újra később.
Cikkek 1–20